Peps
Dulaglutide
Dulaglutide, marketed as Trulicity, is a long-acting GLP-1 receptor agonist used in type 2 diabetes care. Its research includes blood-sugar control and cardiovascular outcomes.
Prescription medicines
Read the risks →Peptides that flag diabetes or blood-sugar medicines
These 24 profiles mention diabetes or blood-sugar medicines in their Risks & interactions section, from the FDA label for approved drugs or from published studies for research compounds. Open a profile and read that section to see exactly why.
A peptide that isn't listed may simply have no human safety data, which doesn't make it safe for you. Dashed tags on investigational GLP-1 drugs come from the labels of approved drugs in the same class. Not medical advice: talk to a doctor or pharmacist about your own situation. All peptides · Heart or blood pressure problems · Blood thinners or bleeding problems · Cancer, now or in the past · Pregnancy or breastfeeding · Kidney problems · Liver problems
Efpeglenatide
Efpeglenatide is an exendin-based GLP-1 receptor agonist. AMPLITUDE-O examined cardiovascular and kidney outcomes in a high-risk type 2 diabetes population.
Research topics
Read the risks →
Exenatide
Exenatide is an incretin medicine used in type 2 diabetes. Short-acting and extended-release products need to be distinguished when reading evidence.
Prescription medicines
Read the risks →
Ghrelin
Ghrelin is a peptide hormone involved in appetite signaling. A small human crossover experiment found higher food intake after an acute infusion.
Research topics
Read the risks →
GHRP-2
GHRP-2 is a synthetic ghrelin-pathway agonist studied for growth-hormone release and eating behavior. Those effects have different practical implications.
Research topics
Read the risks →
GHRP-6
GHRP-6 is a growth-hormone secretagogue with effects extending beyond a single hormone. Human physiology studies help explain that distinction.
Research topics
Read the risks →
Glucagon
Glucagon is a hormone medicine used to raise dangerously low blood glucose. It serves a different role from medicines aimed at lowering glucose or weight.
Prescription medicines
Read the risks →
Human insulin
Human insulin replaces or supplements insulin activity in diabetes. Different formulations have different onset and duration, making product identity especially important.
Prescription medicines
Read the risks →
Lanreotide
Lanreotide is a prescription somatostatin analogue used in specific endocrine and neuroendocrine conditions. Its evidence depends on the disease being treated.
Prescription medicines
Read the risks →
Leuprolide
Leuprolide is a GnRH agonist used to control sex-hormone signaling in several conditions. It belongs to a different pathway from growth-hormone secretagogues.
Prescription medicines
Read the risks →
Liraglutide
Liraglutide is an incretin medicine with distinct diabetes and weight-management product contexts. Its benefits should be tied to the exact indication and population.
Prescription medicines
Read the risks →
Lixisenatide
Lixisenatide is a GLP-1 receptor agonist. ELIXA studied cardiovascular safety in people with type 2 diabetes who had recently experienced an acute coronary event.
Research topics
Read the risks →
Mazdutide
Mazdutide is a dual GLP-1 and glucagon receptor agonist studied for weight management. GLORY-1 tested it in Chinese adults with overweight or obesity.
Research topics
Read the risks →
MK-677
MK-677, or ibutamoren, is a small-molecule ghrelin mimetic. A trial in older adults found increased fat-free mass without an improvement in strength or physical function.
Related compounds
Read the risks →
Octreotide
Octreotide is a somatostatin-related medicine used in specialist endocrine and gastrointestinal care. Immediate- and long-acting preparations have different roles.
Prescription medicines
Read the risks →
Pasireotide
Pasireotide is a somatostatin analogue studied in Cushing disease. The selected trial measured cortisol control and reported frequent hyperglycemia-related events.
Prescription medicines
Read the risks →
Pemvidutide
Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis (MASH). Its liver-biopsy outcomes should be separated from weight-loss claims.
Research topics
Read the risks →
Pramlintide
Pramlintide is an adjunctive diabetes medicine used with mealtime insulin in selected patients. It does not replace insulin.
Prescription medicines
Read the risks →
Retatrutide
Retatrutide is a triple-receptor agonist investigated for obesity and related metabolic conditions. Its trial identity differs from unverified coded seller listings.
Investigational
Read the risks →
Semaglutide
Semaglutide is an incretin medicine with product-specific uses in diabetes, weight management, and other defined conditions. Brand and formulation matter.
Prescription medicines
Read the risks →
Survodutide
Survodutide is a dual GLP-1 and glucagon receptor agonist. A 2026 phase 3 publication reports weight outcomes in adults with obesity or overweight without diabetes.
Research topics
Read the risks →
Tesamorelin
Tesamorelin is a prescription peptide for excess abdominal fat in HIV-associated lipodystrophy. It is not a general weight-loss medicine.
Prescription medicines
Read the risks →
Tirzepatide
Tirzepatide is a dual-incretin medicine with distinct product and indication contexts. Its clinical-trial material is not interchangeable with a research-use vial.
Prescription medicines
Read the risks →
Triptorelin
Triptorelin is a GnRH agonist used for hormone suppression in clinical settings. The featured breast-cancer analysis included several ways of achieving ovarian suppression.
Prescription medicines
Read the risks →See something wrong on this page? Report a mistake · Corrections